Pfizer reported that its dose-optimization studies of once-daily formulations of danuglipron met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase III testing, based on earlier studies of twice-daily danuglipron
Programs may start from a customer-supplied small molecule, an expected metabolite structure, or a labeled-handle concept, and can be aligned with broader amino acid conjugation, custom bioconjugation services, or thiol-reactive route planning informed by maleimide conjugation considerations when appropriate
What are the Risks and Side Effects
This keeps side effects to a minimum, and it is not unusual for patients to experience some of the effects of tirzepatide, such as appetite reduction, in the early stages
Suitable for daily lip care